anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This cross sectional study will evaluate a sample of 360 subjects with luminal Crohn's disease who are receiving infliximab in 15-20 Canadian infusion centres. The sample will be stratified by disease activity \[mild = CDAI \<150, moderate/severe = CDAI ≥150\] and whether or not subjects are on concomitant immunosuppressive therapy. Thus 4 strata will be created consisting of 90 subjects each. Consent will be obtained prior to or at Visit 1, subjects will retrospectively complete a CDAI diary card for the preceding 7 days and blood work will be drawn prior to infliximab infusion. Four weeks thereafter at Visit 2, subjects will provide an additional blood sample to measure serum infliximab concentrations and CRP levels. Between Visits 1 and 3, subjects will complete daily CDAI diary entries. Visit 3 will take place at the next scheduled infusion, 8 weeks after Visit 1 (+/- 7 days ).
In recent years, there has been increased focus on exploring the role the non-protein-coding genome plays in Mendelian disorders. One class of particular interest is long non-coding RNAs (lncRNAs), which has recently been implicated in the regulation of diverse molecular processes. However, because lncRNAs do not encode protein, there is uncertainty regarding what constitutes a pathogenic lncRNA variant, and thus annotating such elements is challenging. The Developmental Genome Anatomy Project (DGAP) and similar projects recruit individuals with apparently balanced chromosomal abnormalities (BCAs) that disrupt or dysregulate genes in order to annotate the human genome. We hypothesized that rearrangements disrupting lncRNAs could be the underlying genetic etiology for the phenotypes of a subset of these individuals. Thus, we assessed 279 cases with BCAs and selected 191 cases with simple BCAs (breakpoints at only two genomic locations) for further analysis of lncRNA disruptions. From these, we identified 66 cases in which the chromosomal rearrangements directly disrupt lncRNAs. In 30 cases, no genes of any other class aside from lncRNAs are directly disrupted, consistent with the hypothesis that lncRNA disruptions could underly the phenotypes of these individuals. Strikingly, the lncRNAs MEF2C-AS1 and ENSG00000257522 are each disrupted in two unrelated cases. Furthermore, we experimentally tested the lncRNAs TBX2-AS1 and MEF2C-AS1 and found that knockdown of these lncRNAs resulted in decreased expression of the neighboring transcription factors TBX2 and MEF2C, respectively. To showcase the power of this genomic approach for annotating lncRNAs, here we focus on clinical reports and genetic analysis of seven individuals with likely developmental etiologies due to lncRNA disruptions.
Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
Systems and methods are provided for identifying one or more health care applications in which a search request is received from a user at a remote client device. The request comprises an alphanumeric query and filtering criteria. A plurality of applications is searched to identify applications that satisfy the filtering criteria and further match the alphanumeric query thereby identifying a set of matching applications. Each respective application in the plurality of applications is (i) for a clinical indication and (ii) includes an evidence score generated by health care providers. The search query response is formatted for display by sorting the matching applications by sorting criteria thereby forming a sorted list of matching applications. At least a portion of the sorting criteria is the evidence score. The search query response, including the sorted list of matching applications, is communicated to the remote client device.
Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to "high" which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature.
Sleep disturbances and suicide are highly prevalent among Veterans and recent research also suggests high comorbid rates of sleep and suicide in Veterans discharged from VA mental health residential rehabilitation treatment programs (MHRRTP; domiciliaries). Nightmares are a frequent concern identified by MHRRTP patients and are a modifiable risk factor for suicide risk. Little is known, however, about the treatment of nightmares and subsequent impact in this setting. The primary aims of the present project are to investigate the efficacy and acceptability of delivering a 2-session intervention to reduce nightmares among Veterans admitted to a MHRRTP. This study will examine this intervention's impact on reducing nightmare distress and nightmare frequency, as well as assess treatment acceptability. Changes in suicide risk following intervention will also be explored. This research will be conducted within the Canandaigua and Bath VA domiciliary programs which currently accommodate \~150-175 Veterans. The study will be a randomized control trial with a hybrid design that uses stratification based on prescription use and randomly assigns individuals (N = 48) to either the treatment group or treatment as usual group (TAU). Veterans referred for the protocol will be screened for eligibility and then if appropriate, scheduled for a baseline evaluation, randomized to either the treatment group or TAU group, seen for two intervention sessions one week apart, and then be followed up with 4- and 8-weeks post initial treatment via telephone. This research has potential to highlight valuable targets for cross-cutting treatment in a rehabilitation setting that can be delivered in civilian and Veteran samples.
BACKGROUND: Early diagnosis of postoperative acute kidney injury (AKI) is crucial. This study investigated the changes and early diagnostic value of Doppler ultrasound parameters in patients with AKI after laparoscopic radical prostatectomy (LRP).
METHODS: This study retrospectively analysed the clinical data of 198 patients with LRP undergoing Doppler ultrasound from May 2020 to May 2022. The incidence of AKI after LRP was measured based on diagnostic criteria of AKI developed by Kidney Disease: Improving Global Outcomes. The patients were divided into AKI group (n = 12) and non-AKI group (n = 186) in accordance with the presence or absence of AKI. This study compared changes in Doppler ultrasound parameters between two groups, and evaluated the clinical efficacy of single and combined diagnosis of ultrasound parameters using receiver operating characteristic (ROC) curve and area under the curve (AUC).
RESULTS: Twelve patients experienced postoperative AKI, with an incidence rate of 6.06%. No significant difference was found in baseline data, serum creatinine (Scr), urinary output and blood potassium levels of both groups (p > 0.05). The urinary output 1 day after surgery was significantly lower than that before surgery (p < 0.05). The AKI group demonstrated higher pulsatility index (PI) and resistive index (RI) of the renal interlobar artery than the non-AKI group (p < 0.05), with no significant difference in peak systolic velocity (PSV) in both groups (p > 0.05). No significant difference was observed in the Doppler ultrasound parameters of renal segmental artery and main renal artery (p > 0.05). The AUCs in the PI of the renal interlobar artery, the RI of the renal interlobar artery, and the combined diagnosis were 0.720, 0.704 and 0.724, respectively. ROC curve showed that the above two Doppler ultrasound parameters had good diagnostic efficacy for AKI after LRP (p < 0.05).
CONCLUSIONS: The PI and RI of renal interlobar artery in the AKI group after LRP were significantly different from those in the non-AKI group. These two Doppler ultrasound parameters had good diagnostic efficacy in the early identification of AKI after LRP. Thus, they could provide reference and guidance for clinical practice.
Friedreich's ataxia (FA) is an autosomal recessive ataxia caused by a trinucleotide GAA expansion in the first intron of the FXN gene. The gene encodes for a 210aa mitochondrial protein called frataxin, whose mRNA and protein levels are severely reduced in FA. It has been suggested that frataxin is involved in iron-sulphur cluster and heme biogenesis, iron binding/storage, and chaperone activity. Clinically, the age of onset is generally around puberty and, as the disease progresses, there is increasing ataxia of the limbs, and eventually most patients are wheelchair bound by the twenties. Cardiomyopathy with myocardial hypertrophy occurs very often and is the predominant cause of death. Type II diabetes, scoliosis, foot deformities, optic atrophy, and deafness are other relatively frequent symptoms.

Erythropoietin (EPO) is a glycoprotein that acts as a main regulator for erythropoiesis. Evidence suggests that both EPO and its receptor are expressed in the nervous tissue, and neuroprotective effects have been shown in animal models of cerebral ischemic damage. EPO increases frataxin levels in cultured human lymphocytes from FRDA patients. However, frataxin protein increase is not preceded by mRNA increase, suggesting that a post-transcriptional mechanism is involved. To date, four phase II clinical trials have been published regarding the use of EPO in FRDA patients.
The invention discloses a medical ointment for curing burn and scald. The medical ointment takes sesame raw oil as basic medium and the part by weight as the unit, which comprises cortex lycii radicis 200-400 parts, dodder 200-400 parts, dried big malt 200-500 parts, calcined alum 100-400 parts and baras camphor 15-30 parts. The raw medicines are ground into fine powder after being treated, and the fine powder is mixed, stirred evenly and sterilized, finally the fine powder is mixed with sesame raw oil. The weight proposition of the disinfected mixed fine powder and the sesame raw oil is 1: 1 to 1: 7. The invention has the advantages of little medical ointment dispensation, simple preparation process and easy implementation of application and popularization. The medical ointment of the invention is applicable to various types of burn and scald, and deep burn and scald without grafting shin, and the curing effect is obvious. Any scar can not be left after being cured, the function of organs is recovered to be normal, and in particular the recovery of sweat gland is new as well as the original after being cured.
Loading doses of 30 mg/kg IV on Day 8 (with +/- 2 days window), and 15 mg/kg IV on Day 15. The subcutaneous (SC) administration of 600 mg (2 injections of 2 mL CFZ533 at 150 mg/mL) every 2 weeks started on Day 29, in combination with MMF and CS up to EOS.
PURPOSE:To provide a cosmetic for hair, containing a compound selected from a xanthine compound, papaverine, 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone, etc., and an alcohol or fatty acid, etc., having odd number carbon chain length. CONSTITUTION:The objective composition for hair having high safety and excellent effect in preventing and ameliorating gray hair is produced by using (A) 0.01-5wt.% of a compound selected from a compound having a principal skeleton of formula (e.g. xanthine), papaverine, its salt, papaveraldine, its salt, 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and its salt and (B) 0.1-10wt.% of a compound selected from a fatty acid, an alcohol and their derivative having an odd number carbon chain length. The weight ratio of the component A/B is 1/500-50/1. The component B is e.g. pentadecanoic acid monoglyceride.
The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data in these participants.
Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
Diabesity is a condition where an individual has both diabetes and obesity, which can lead to severe complications including cardiovascular disease, a leading cause of mortality. Recently, cancer has become a leading cause of excess hospitalizations, and both diabetes and obesity are associated with a higher risk of developing several types of cancer. In this review, we propose that chronic stress significantly increases this association. Managing diabetes and obesity is challenging as they both cause significant distress. The relationship between stress and cancer is interconnected, with anxiety and depression being common in cancer patients. Cancer diagnosis and treatment can cause lasting changes in the body's neuroendocrine system, with stress causing an excessive release of catecholamines and prostaglandins in patients undergoing cancer surgery, which promotes the spread of cancer to other parts of the body. Furthermore, stress could significantly increase the risk of cancer in patients with diabetes, obesity, or both.
Technology is making possible new approaches to overcome old public health challenges. Cellular networks are now ubiquitous in resource-poor settings and offer new opportunities for high-yield interventions for both chronic and acute diseases. We are specifically interested in developing mHealth solutions for diarrheal disease for two reasons. The first reason is that diarrheal disease globally remains the second leading cause of death for children less than 5 years of age. Barriers to combat this problem include poor adherence to guidelines for rehydrating children and outbreaks often outpace current epidemiological tools. The second reason is that diarrheal diseases in a setting like Bangladesh, including cholera outbreaks, are a model system to develop and test mHealth solutions that can be adapted to more complex chronic and acute diseases in Bangladesh and globally.

In partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b; primary collaborator) and the Institute of Epidemiology, Disease Control, Research (IEDCR) within the Ministry of Health and Family Welfare in Bangladesh, we propose to compare a paper-based versus a smartphone-based decision-support tool in a cluster randomized controlled trial (cRCT) to determine the impact of the method of decision-support on the use of IV fluids (primary outcome) and indicated medications (secondary outcomes). The smartphone tool is an adaptation of the paper-based World Health Organization guidelines, and is called the 'Rehydration Calculator.' The cRCT will be conducted collaboratively between the icddr,b and government hospitals (N=10) in Bangladesh over 4.5 months per site. A 6-week pre-intervention period will establish a baseline at all sites, and in the intervention, hospitals will be randomized to use the paper versus smartphone tool by the admitting physician. Inclusion criteria are patients 2 months and older that have uncomplicated acute diarrheal disease; estimated enrollment is 7893 patients. Standard of care will be practiced at all sites, with the exception of the decision-support tool(s) in the interventional period. The primary outcome measure is use of IV fluids. This project may have broad impact that will include opportunities to provide improved decision-support for the assessment of dehydration, decrease intravenous fluid use and improve antibiotic stewardship.
PCT No. PCT/US94/12232 Sec. 371 Date Apr. 26, 1996 Sec. 102(e) Date Apr. 26, 1996 PCT Filed Oct. 26, 1994 PCT Pub. No. WO95/11694 PCT Pub. Date May 4, 1995Conjugated compounds which comprise an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer are disclosed. Methods of radioimaging metastasized colorectal cancer cells are disclosed. In vitro methods, kits and reagents are disclosed for determining whether or not an individual has metastasized colorectal cancer cells, for determining whether tumor cells are colorectal in origin and for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells.
The invention relates to a method for treatment of perianal eczema. The method is characterized in that it involves the following components: 50g of fresh folium artemisiae argyi, 30g of raw Sanguisorba officinalis, 30g of purslane, 20g of Common Cnidium Fruit, 20g of zanthoxylum, 20g of dried alum, 20g of artemisia capillaries, 20g of mirabilite, 10g of zanthoxylum, 10g of folium artemisiae argyi, and 10g of alum. The method includes: adding 2000ml of water to the drugs and conducting cooking till boiling, taking a cup of juice, when the temperature drops, putting a small amount of radix isatidis granules into the cup, and stirring the mixture evenly. The product is used for coating an affected part three times a day for 5 days as a course of treatment. The method is applied to 35 people, and takes effect in 28 cases. The method provided by the invention provides a solution to the circumstances that existing traditional treatment methods are based on inflammation reduction by antibiotics or endocrine conditioning by traditional Chinese medicines, have large side effects on the human body, disorder metabolism of a patient's body, reduce the human body immunity, or even cause other complications, and common ointments for external use have slow effect and unsatisfactory treatment effect.
During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve9. The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus. Evidence to date shows that FICB and PENG may be effective modalities to provide postoperative pain control following THA and could reduce opioid consumption10. The above procedures have been documented as safe and effective when performed by a qualified anesthetist but come with various risks (potential motor / sensory blocade especially) and associated cost. Alternatively, or in conjunction to the above procedures, the orthopedic surgeon can perform local anaesthetic infiltration (LAI) into the anterior pericapsular tissues. To date, no study has compared the efficacy of FICB, PENG block and LAI in a randomized study, therefore a preferred postoperative analgesic regimen has yet to be determined.

In this randomized trial, the investigators aim to evaluate postoperative pain and side effects related to pain control in patients who receive FICB versus LAI versus PENG block following THA. The investigators aim to compare these procedures between each other and assertain whether these techniques compare favourably to spinal anesthetic as a control group.
<P>PROBLEM TO BE SOLVED: To provide a dispersion of an inorganic pigment typified by zinc oxide or titanium oxide, excellent in dispersibility and stability with the lapse of time, forming coat excellent in transparency and suitable especially for cosmetic use, and to provide a method for producing the dispersion.  <P>SOLUTION: The pigment dispersion comprises a solvent and 5-60 pts.wt. silicone having a reactive substituent per 100 pts.wt. inorganic pigment having 5-100 nm average primary particle diameter, wherein, when forming a film having 3 μm dry film thickness by using the pigment dispersion, the film has ≤5% haze. The method for producing the pigment dispersion comprises kneading a mixture of an inorganic pigment having 5-100 nm average primary particle diameter with a silicone having a reactive substituent by using two rolls, and dispersing the obtained kneaded product in a solvent, wherein the nonvolatile in the kneaded products is ≥75 wt.%.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
FIELD: medicine.SUBSTANCE: inventions refer to medicine. A method for cognitive behaviour therapy of insomnia is implemented by a cognitive behaviour therapy system. The cognitive behaviour therapy system comprises an electronic communication device, a sensor system for detecting sleep activity data, a first processing unit for sleep activity data transformation into sleep structure data, a second processing unit with an entry unit for patient's input data collection, including those specifying the assessment of the patient's insomnia impact on patient's daily activity, a third processing unit for sleep structure and patient's input data reception, analysis and patient's sleep profiling, a fourth processing unit for patient's sleep profile analysis and therapeutic assistance, and a display. A memory device of the fourth processing unit comprises a set of therapeutic instruction units to be presented on the display. The fourth processing unit is configured to arrange the therapeutic instruction units on the basis of the above patient's sleep profile and to present the arranged therapeutic instruction units on the display. The patient's sleep is controlled by means of the sensor system; the patient's input data are collected by means of the entry unit; the patient's input data and the sleep activity data are combined to create the patient's sleep profile; the above profile is analysed to specify a therapeutic course to be presented to the patient on the display thereafter.EFFECT: using the inventions is supposed to provide the more accurate assessment of the patient's state and to facilitate the cognitive behaviour therapy for the patient.19 cl, 12 dwg
The study group included patients with low back pain for less than 3 months. The control group consists of healthy volunteers.